Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers.
about
Recent updates of precision therapy for gastric cancer: Towards optimal tailored managementTargeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapies.
P2860
Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Phase II trial of everolimus i ...... ole for predictive biomarkers.
@ast
Phase II trial of everolimus i ...... ole for predictive biomarkers.
@en
type
label
Phase II trial of everolimus i ...... ole for predictive biomarkers.
@ast
Phase II trial of everolimus i ...... ole for predictive biomarkers.
@en
prefLabel
Phase II trial of everolimus i ...... ole for predictive biomarkers.
@ast
Phase II trial of everolimus i ...... ole for predictive biomarkers.
@en
P2093
P2860
P1476
Phase II trial of everolimus i ...... ole for predictive biomarkers.
@en
P2093
Andre Liem
Brian DiCarlo
David J Park
Diego Martinez
He-jing Wang
Heloisa P Soares
Isett Laux
J Randolph Hecht
Lisa Yonemoto
Meghan Brennan
P2860
P2888
P356
10.1007/S00280-015-2744-5
P577
2015-05-13T00:00:00Z
P6179
1005963661